Hepatology

REACH is an experienced thought leader in the hepatology space. Our team has conducted research across many hepatologic diseases, both rare and non-rare

DISEASES WE COVER

Hepatology has evolved from a focus on curing Hepatitis C to the next major threat within hepatology – Nonalcoholic Fatty Liver Disease (NAFLD). Current hepatology dynamics the REACH team is tracking include:

The rising global prevalence of NAFLD
Potential for a long-awaited FDA approval for Nonalcoholic Steatohepatitis (NASH) with Madrigal Pharmaceuticals’ resmetirom
Autoimmune liver diseases with high unmet therapeutic need (e.g., Primary Biliary Cholangitis, Primary Sclerosing Cholangitis

See our rare hepatology solutions

Search Hepatology diseases we cover

Disease

Alagille Syndrome

Autoimmune Hepatitis

Biliary Atresia

Primary Biliary Cirrhosis

Primary Sclerosing Cholangitis

Don’t see your disease of interest? Don’t worry! Our experienced team can provide market research support for any rare disease. Reach out to learn how we can help.

Disease

Alagille Syndrome

Autoimmune Hepatitis

Biliary Atresia

Don’t see your disease of interest? Don’t worry! Our experienced team can provide market research support for any rare disease. Reach out to learn how we can help.

Browse contacts:

1 2 Next »

Schedule a hepatology demo with our team

OUR SOLUTIONS

Market Landscape Assessment

MarketVue® reports capture the current and anticipated future state of any rare hepatology market

Learn More

Epidemiology

EpiVue® reports quantify prevalence, diagnosis, treatment rates and patient segments for rare hepatologic conditions

Learn More

Indication Prioritization

MarketSheet® single-sheet market primers for any hepatology disease allow easy comparison across the hepatology therapy area

Learn More

Custom Rapid Insights

Fast turnaround primary market research for a focused set of questions for hepatologist or payers

Learn More

Reach out to our team to learn more about our capabilities and view sample reports.